Based on our study we found that in situ vaccination with the combination of agonistic anti-OX40 and the TLR9 ligand unmethylated CpG oligodeoxynucleotide can be effective in case of the MB49 bladder cancer cell line in a mouse model. Here, TLR9 is linked to urinary bladder carcinoma.